Latest Pancreatic Cancer News

OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Arovella Therapeutics reported solid progress in Q1 FY26, moving closer to initiating its first-in-human trial for ALA-101 while securing key patents and maintaining a strong cash position.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

OncoSil Medical Limited has addressed ASX concerns over delayed disclosure of PANCOSIL clinical trial results, confirming compliance with continuous disclosure obligations despite procedural oversights.

Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.

Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.